drugset / Trial / NCT06716970
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2026-04-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QR12000 | Unknown | 75 mg | — |
| Subject | QR12000 | Unknown | 150 mg | — |
| Comparator | Sacubitril/valsartan | Unknown | 200 mg | — |